NTRA
Natera, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$325.55
−0.65%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.7B | 2.3B | 1.7B | 1.1B | 820.2M |
| Cost of Revenue | 939.2M | 810.6M | 673.8M | 589.8M | 456.3M |
| Gross Profit | 1.8B | 1.5B | 1.0B | 492.7M | 364.0M |
| Operating Expenses | |||||
| R&D Expense | 787.4M | 624.1M | 404.1M | 320.7M | 316.4M |
| SG&A Expense | 1.3B | 1.2B | 841.3M | 618.3M | 588.6M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 15.1M | 4.0M | — | — | — |
| Total Operating Expenses | 2.1B | 1.8B | 1.2B | 939.0M | 905.0M |
| Cost and Expenses | 3.0B | 2.6B | 1.9B | 1.5B | 1.4B |
| Operating Income (EBIT) | (289.7M) | (309.9M) | (222.3M) | (446.2M) | (541.0M) |
| Non-Operating | |||||
| Interest Income | 54.5M | 45.9M | 43.2M | 24.4M | 3.5M |
| Interest Expense | 10.0M | 4.1M | 10.7M | 12.6M | 9.3M |
| Net Interest Income | 44.5M | 41.8M | 32.6M | 11.7M | (5.8M) |
| Other Non-Op Income/Expense | 37.0M | 41.8M | 32.6M | 11.7M | (5.8M) |
| Non-Operating Income (excl Interest) | (45.2M) | (45.9M) | (43.2M) | (24.4M) | (3.5M) |
| EBT (Pre-Tax Income) | (252.7M) | (268.1M) | (189.7M) | (434.5M) | (546.8M) |
| Income Tax Expense | (60.4M) | (59.9M) | 695.0K | 271.0K | 978.0K |
| Bottom Line | |||||
| Net Income | (192.3M) | (208.2M) | (190.4M) | (434.8M) | (547.8M) |
| Earnings from Cont. Ops | (192.3M) | (208.2M) | (190.4M) | (434.8M) | (547.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (192.3M) | (208.2M) | (190.4M) | (434.8M) | (547.8M) |
| Per Share | |||||
| Basic EPS | ($1.36) | ($1.52) | ($1.53) | ($3.78) | ($5.57) |
| Diluted EPS | ($1.36) | ($1.52) | ($1.53) | ($3.78) | ($5.57) |
| Revenue Per Share | $18.89 | $16.87 | $13.61 | $9.41 | $8.33 |
| Shares | |||||
| Basic Shares Outstanding | 143.3M | 136.7M | 124.7M | 115.0M | 98.4M |
| Diluted Shares Outstanding | 143.3M | 136.7M | 124.7M | 115.0M | 98.4M |
| Profitability Metrics | |||||
| EBITDA | (179.1M) | (220.5M) | (148.1M) | (383.3M) | (507.0M) |
| D&A | 65.4M | 43.5M | 31.0M | 38.6M | 30.5M |
| EBIT | (244.5M) | (264.0M) | (179.0M) | (421.9M) | (537.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026